Senexin-A

Research use only, not for human use.

A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.

A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively; inhibits only p21-induced transcription but not other biological effects of p21, inhibits β-catenin-dependent transcription in HCT116 colon carcinoma cells; suppresses damage-induced tumor-promoting paracrine activities of tumor cells and normal fibroblasts and reverses the increase in tumor engraftment and serum mitogenic activity in mice pretreated with doxorubicin.

——

——

Senexin A

Angiogenesis

CDK

CDK

——

——

1366002-50-7

274.32

C17H14N4

>98% (HPLC)

DMSO: ≥100 mg/mL

N#CC1=CC2=C(NCCC3=CC=CC=C3)N=CN=C2C=C1

6-Quinazolinecarbonitrile, 4-[(2-phenylethyl)amino]-

(-20℃)

With Ice Pack

≥ 2 years